查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1638737

抗菌素抗药性诊断市场机会、成长动力、产业趋势分析和 2024 年至 2032 年预测

Antimicrobial Resistance Diagnostics Market Opportunity, Growth Drivers, Industry Trend Analysis, and Forecast 2024 to 2032
出版日期: | 出版商: Global Market Insights Inc. | 英文 140 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023 年，全球抗生素抗药性诊断市场价值为44 亿美元，预计2024 年至2032 年复合年增长率将超过6.3%。需求不断增加治疗和诊断技术的重大进步。

市场分为两个主要产品类别：仪器和消耗品以及试剂盒和试剂。 2023 年，试剂盒和试剂领域以 28 亿美元的价值引领市场。这些诊断试剂盒和试剂对于快速、准确地鑑定抗生素抗药性菌株发挥至关重要的作用。早期发现抗药性对于确保有效的治疗方案和减少抗生素的过度使用至关重要，抗生素的过度使用是产生抗药性的主要因素。全球和区域的努力，例如卫生组织的倡议，正在进一步推动对抗菌素抗药性诊断工具的需求。

在研究抗菌素抗药性诊断中使用的技术时，市场分为微生物培养、免疫测定、PCR、次世代定序 (NGS)、质谱、快速和护理点诊断以及其他技术。到2023年，微生物培养领域将占据31.1%的显着份额。培养系统的自动化显着减少了诊断所需的时间，使基于培养的方法在检测抗生素抗药性细菌方面更加可靠，预计这将进一步推动市场成长。

市场范围
开始年份 2023年
预测年份 2024-2032
起始值 44亿美元
预测值 76 亿美元
复合年增长率 6.3%

美国抗菌素抗药性诊断市场预计将以6.2% 的复合年增长率成长，到2032 年将达到31 亿美元。 (CARB)，做出了贡献扩大 AMR 诊断能力。这些措施支持诊断技术的进步，并为该领域的研究和开发提供资金。此外，美国卫生与公共服务部已承诺大量投资，以加强 AMR 诊断、研究和新型抗生素的开发，进一步推动市场成长。

目录

第 1 章：方法与范围

第 2 章：执行摘要

第 3 章：产业洞察

  • 产业生态系统分析
  • 产业影响力
    • 成长动力
      • 抗药性感染发生率增加
      • 诊断技术的进步
      • 提高医疗机构的意识和培训计划
    • 产业陷阱与挑战
      • 开发和实施成本高
      • 来自替代解决方案的竞争
  • 成长潜力分析
  • 监管环境
  • 未来市场趋势
  • 技术景观
  • 波特的分析
  • PESTEL分析

第 4 章：竞争格局

  • 介绍
  • 公司市占率分析
  • 公司矩阵分析
  • 主要市场参与者的竞争分析
  • 竞争定位矩阵
  • 战略仪表板

第 5 章：市场估计与预测：按产品类型，2021 - 2032 年

  • 主要趋势
  • 试剂盒和试剂
  • 仪器及耗材

第 6 章：市场估计与预测：按技术分类，2021 - 2032 年

  • 主要趋势
  • 微生物培养
  • 免疫分析
  • 聚合酶炼式反应 (PCR)
  • 下一代定序（NGS）
  • 质谱分析
  • 快速和护理点
  • 其他技术

第 7 章：市场估计与预测：按病原体类型，2021 - 2032 年

  • 主要趋势
  • 抗药性肺炎链球菌 (DRSP)
  • 抗药性弯曲桿菌 (DRC)
  • 艰难梭菌 (CD)
  • 抗药性淋病奈瑟菌 (DRNG)
  • 其他病原体类型

第 8 章：市场估计与预测：按最终用途，2021 - 2032 年

  • 主要趋势
  • 医院和诊所
  • 诊断实验室
  • 製药和生物技术公司
  • 其他最终用户

第 9 章：市场估计与预测：按地区，2021 - 2032

  • 主要趋势
  • 北美洲
    • 我们
    • 加拿大
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 荷兰
  • 亚太地区
    • 中国
    • 日本
    • 印度
    • 澳洲
    • 韩国
  • 拉丁美洲
    • 巴西
    • 墨西哥
    • 阿根廷
  • 中东和非洲
    • 南非
    • 沙乌地阿拉伯
    • 阿联酋

第 10 章：公司简介

  • Abbott Laboratories
  • Accelerated Diagnostics, USA
  • Alifax
  • Bio-Rad Laboratories
  • BioMerieux
  • Beckman Coulter
  • Becton, Dickinson and Company
  • F. Hoffmann-La Roche
  • GeneFluidics
  • Molsid
  • Thermo Fisher Scientific
  • Vela Diagnostics
简介目录
Product Code: 12145

The Global Antimicrobial Resistance Diagnostics Market was valued at USD 4.4 billion in 2023 and is projected to expand at a CAGR of over 6.3% from 2024 to 2032. The market is driven by the growing incidence of antibiotic-resistant infections, the increasing demand for personalized treatments, and significant advancements in diagnostic technologies.

The market is divided into two main product categories: instruments & consumables and kits & reagents. In 2023, the kits & reagents segment led the market with a value of USD 2.8 billion. These diagnostic kits and reagents play a crucial role in the rapid and accurate identification of antibiotic-resistant bacterial strains. Early detection of resistance is essential for ensuring effective treatment regimens and reducing the overuse of antibiotics, which is a primary factor in the development of resistance. Global and regional efforts, such as initiatives from health organizations, are further driving the demand for AMR diagnostic tools.

When examining the technologies used in antimicrobial resistance diagnostics, the market is segmented into microbiology culture, immunoassay, PCR, next-generation sequencing (NGS), mass spectrometry, rapid & point-of-care diagnostics, and other technologies. The microbiology culture segment held a significant share of 31.1% in 2023. Technological advancements in microbial culture have greatly improved the speed, accuracy, and specificity of identifying resistant strains. The automation of culture systems has notably reduced the time required for diagnostics, making culture-based methods more reliable in detecting antibiotic-resistant bacteria, which is expected to further propel market growth.

Market Scope
Start Year2023
Forecast Year2024-2032
Start Value$4.4 Billion
Forecast Value$7.6 Billion
CAGR6.3%

U.S. antimicrobial resistance diagnostic market is projected to grow at a CAGR of 6.2%, reaching USD 3.1 billion by 2032. U.S. government initiatives focused on combating antibiotic resistance, such as the National Action Plan for Combating Antibiotic-Resistant Bacteria (CARB), have contributed to the expansion of AMR diagnostic capabilities. These initiatives support advancements in diagnostic technologies and provide funding for research and development in the field. Additionally, the U.S. Department of Health and Human Services has committed substantial investments to enhance AMR diagnostics, research, and the development of novel antibiotics, further boosting market growth.

Table of Contents

Chapter 1 Methodology & Scope

  • 1.1 Market scope & definitions
  • 1.2 Research design
    • 1.2.1 Research approach
    • 1.2.2 Data collection methods
  • 1.3 Base estimates & calculations
    • 1.3.1 Base year calculation
    • 1.3.2 Key trends for market estimation
  • 1.4 Forecast model
  • 1.5 Primary research and validation
    • 1.5.1 Primary sources
    • 1.5.2 Data mining sources

Chapter 2 Executive Summary

  • 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

  • 3.1 Industry ecosystem analysis
  • 3.2 Industry impact forces
    • 3.2.1 Growth drivers
      • 3.2.1.1 Increasing incidence of drug-resistant infection
      • 3.2.1.2 Advancement in diagnostic technology
      • 3.2.1.3 Rising awareness and training programs in healthcare facilities
    • 3.2.2 Industry pitfalls & challenges
      • 3.2.2.1 High development and implementation cost
      • 3.2.2.2 Competition from alternative solutions
  • 3.3 Growth potential analysis
  • 3.4 Regulatory landscape
  • 3.5 Future market trends
  • 3.6 Technology landscape
  • 3.7 Porter's analysis
  • 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

  • 4.1 Introduction
  • 4.2 Company market share analysis
  • 4.3 Company matrix analysis
  • 4.4 Competitive analysis of major market players
  • 4.5 Competitive positioning matrix
  • 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product Type, 2021 - 2032 ($ Mn)

  • 5.1 Key trends
  • 5.2 Kits & reagents
  • 5.3 Instruments & consumables

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

  • 6.1 Key trends
  • 6.2 Microbiology culture
  • 6.3 Immunoassay
  • 6.4 Polymerase chain reaction (PCR)
  • 6.5 Next generation sequencing (NGS)
  • 6.6 Mass spectrometry
  • 6.7 Rapid & point of care
  • 6.8 Other technologies

Chapter 7 Market Estimates and Forecast, By Pathogen Type, 2021 - 2032 ($ Mn)

  • 7.1 Key trends
  • 7.2 Drug-resistant streptococcus pneumoniae (DRSP)
  • 7.3 Drug-resistant campylobacter (DRC)
  • 7.4 Clostridium difficile (CD)
  • 7.5 Drug-resistant neisseria gonorrhoeae (DRNG)
  • 7.6 Other pathogen types

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

  • 8.1 Key trends
  • 8.2 Hospitals & clinics
  • 8.3 Diagnostic laboratories
  • 8.4 Pharmaceutical & biotechnology companies
  • 8.5 Other end users

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

  • 9.1 Key trends
  • 9.2 North America
    • 9.2.1 U.S.
    • 9.2.2 Canada
  • 9.3 Europe
    • 9.3.1 Germany
    • 9.3.2 UK
    • 9.3.3 France
    • 9.3.4 Spain
    • 9.3.5 Italy
    • 9.3.6 Netherlands
  • 9.4 Asia Pacific
    • 9.4.1 China
    • 9.4.2 Japan
    • 9.4.3 India
    • 9.4.4 Australia
    • 9.4.5 South Korea
  • 9.5 Latin America
    • 9.5.1 Brazil
    • 9.5.2 Mexico
    • 9.5.3 Argentina
  • 9.6 Middle East and Africa
    • 9.6.1 South Africa
    • 9.6.2 Saudi Arabia
    • 9.6.3 UAE

Chapter 10 Company Profiles

  • 10.1 Abbott Laboratories
  • 10.2 Accelerated Diagnostics, USA
  • 10.3 Alifax
  • 10.4 Bio-Rad Laboratories
  • 10.5 BioMerieux
  • 10.6 Beckman Coulter
  • 10.7 Becton, Dickinson and Company
  • 10.8 F. Hoffmann-La Roche
  • 10.9 GeneFluidics
  • 10.10 Molsid
  • 10.11 Thermo Fisher Scientific
  • 10.12 Vela Diagnostics